The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

Exascend, a leader in innovative high-performance storage and memory solutions, proudly announces the AEC-Q100 certification of AS500 series automotive-grade HSBGA SSD (Heat Sink Ball Grid Array solid ...

Archer-Daniels-Midland Co. restated previous earnings, after earlier this month identifying new accounting errors, in a key ...

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FR?) positive, platinum-resistant ovarian cancerELAHERE represents the ...

Latest news on the coronavirus, which has killed millions during a global pandemic.